U.S. Markets closed

ChemoCentryx, Inc. (CCXI)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.95-0.12 (-1.70%)
At close: 4:00PM EDT

6.95 0.00 (0.00%)
After hours: 4:00PM EDT

People also watch
VSTMEPZMRGLSCEMPCLRB
  • (AXSM) Market Cap $92 M/Cash $55 M / 5x BIG Phase 3 programs in various indications targeting large Markets with first results in Q3 2017 =20 BAGGER ..FANTASTIC OPPORTUNITY !

    Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $92 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .

    This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL

    Axsome (AXSM)

    Market-Cap: $92 Million
    Cash: $55 Million(cash runway into the first quarter of 2019.)
    Price:$4.10

    Shares Out: 23.5 Million

    Anticipated Near-Term Clinical Milestones

    Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)

    Clinical Trial Readouts:

    -- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)

    -- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)

    -- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)

    New Presentation May
    http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NjcwNTc4fENoaWxkSUQ9Mzc3ODc0fFR5cGU9MQ==&t=1

    HUGE Pipeline targeting Billion Dollar Markets:
    http://axsome.com/wp-content/uploads/2016/11/Axsome_Dec2016_Pipeline.png

    AXS-05 Treatment Resistant Depression in Phase 3......Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.

    AXS-05 Agitation in Alzheimer’s Disease in Phase 2/3.......No approved medication = unmet medical need. 2M patients in the U.S.

    AXS-02 Complex Regional Pain Syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status).......No approved drug = high unmet need. 80,000 new cases per year in the U.S.

    AXS-02 Knee Osteoarthritis (OA) with Bone Marrow Lesions (BMLs) in Phase 3 (SPA & Fast Track).........7M patients in the U.S.

    AXS-02 Chronic Low Back Pain(CLBP) with Modic Changes (MCs) in Phase 3 ......1.6M patients in the U.S.

  • Got a great report from http://thesubwaytrader.com/?s=CCXI about $CCXI. I did have to subscribe but it was worth the time. Thank you guys for the tip! Malek's law: any simple idea will be worded out in the most complicated way. Trading stocks day trading.

    The Subway Trader: Trading Stocks and Making Money
    Stock alerts from the The Subway Trader. Stock trading, making money and always looking for the next big money maker.
    thesubwaytrader.com
  • My volume on the portfolio view page says we traded 1,493,410,421 shares today.
  • Intelligentia est, ut indusia, quilibet debet habere, http://dataunion.tistory.com/1445

    [2016-MAY] ChemoCentryx Inc NASDAQ : CCXI Correlation Histogram
    X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is -0.7 In other words, the correlation coefficient of the other stoc
    dataunion.tistory.com
  • Did anybody listen to the call? Their progress seems solid and profitability in the not too distant future doesn't seem to be that big a stretch. Enough cash in the bank to fund three years of operations. Yet it's so sleepy. I could use a little good news in my portfolio about now. Please somebody notice!
  • Thanks for the tip, I did some research and found more information about $CCXI on http://monstastocks.com/?s=CCXI Trading stocks investing. Kohn's corolarry to murphy's law: two wrongs are only the beginning.

    Monsta Stocks: Trading Stocks and Making Money
    Stock alerts from the Monsta Stocks. Stock trading, making money and always looking for the next big money maker.
    monstastocks.com
  • Downside risk pretty much eliminated now that CCXI has seen target price reached the lower limits of 10.00. Yo you should really check out awesomeSTO-CKS, they seem on point with their stocks.
  • If you look at the chart, CCXI has been here before. GSK was the last horse to fund them and pulled out after lack luster results on CCX140. The stock collapsed (look at the chart). Now with over $100M in the bank to get the PIII done, its simply a wait and see game. How the market values this is anyone's guess and I've seen plenty of instances where a company is well funded like this and just drifts lower and lower as less people belive in their ability to get the PIII done by 2019.
  • 5 cents? this company gets no respect...nice news today...
  • price has been dropping steadily over the last month and it is kind of concerning..i did not hear any negative news...
  • Perhaps a light will be shined on sleeping beauty at JPM next week. We sure do have a solid balance sheet these days and prospects like we haven't before. Sooner or later somebody's going to notice.
  • Halted?
  • nice deal with Vifor. $50M upfront. That is not chump change...
  • There's something happening here. What it is ain't exactly clear.
  • I want $9- we shall see $8.90 and then computers will decide?
  • $CCXI....Hear Me out…If you arThey don’t want you to know about loin stock alertsq (google them) because these guys are the best at what they do. They only alert trending momentum stocks, NO BS and no fluff…
  • 10 for Christmas
  • Break-Dance- MJ- new high thriller$
  • Ahus -Kidney data from presentation found on Seeking Alpha-
  • Seeking Alpha- aHUS is an ultra-rare disease with just 300 patients in the U.S. and an estimated 140,000 worldwide. Soliris is currently the only approved treatment for aHUS. Soliris has been priced at $550,000 and also has an Orphan Drug designation from the U.S. FDA. Interestingly, CCX168 has also been granted an Orphan Drug designation in aHUS. An Orphan Drug provides a drug 7-year exclusivity, however, the FDA can grant an Orphan Drug designation to another drug if it can exhibit clinical superiority. This is according to a 1992 Amendment to the 1983 Orphan Drug Act.